Canopy Growth 2Q Loss Narrows, Canadian Cannabis Sales Up

Dow Jones11-07
 

By Adriano Marchese

 

Canopy Growth's loss narrowed in its fiscal second quarter thanks to strong performance in both medical- and recreational-cannabis sales in Canada.

For the three months ended Sept. 30, the Smiths Falls, Ontario, cannabis company on Friday posted a significantly narrowed net loss of 1.64 million Canadian dollars ($1.12 million), or C$0.01 a share, compared with a loss of C$128.3 million, or C$1.48 a share, in the comparable quarter a year earlier.

According to FactSet, analysts were expecting a loss of C$0.16 a share.

Consolidated net revenue rose 6% to C$66.7 million, but fell short of analyst expectations for a greater rise to C$71.2 million.

Canopy said it saw a 30% rise in Canadian adult-use cannabis revenue, to C$24 million, thanks largely to growth in infused preroll joints and new all-in-one vapes. Canadian medical cannabis also got a boost, with revenue rising 17% to C$22 million as it benefited mainly from more insured patients and larger order sizes.

On the international front, Canopy faced supply-chain issues in Europe that dragged revenue down 39% to C$5 million.

Meanwhile, vaporizer brand Storz & Bickel's net revenue fell 10% in the quarter. The brand was up against strong year-earlier figures, as well as continued economic uncertainty in its key markets.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

November 07, 2025 07:56 ET (12:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment